



SHOULD YOU CONSIDER EARLY TIPS FOR YOUR VARICEAL BLEEDING PATIENTS?

Trial or study	Survival at one year	Prevention of rebleeding	Incidence of hepatic encephalopathy (HE) compared to pharmacotherapy combined with endoscopic therapy
Randomized Control Trial (RCT) ¹	86% [*]	97% [‡]	No significant difference
Post-RCT Surveillance Study ²	86% [*]	93% [§]	No significant difference
Observational Study ³	78% ^{*,†}	92%	No significant difference

All results above were reported at one year.

Remarkably, the number of patients needed
to be treated to save one life is four.³
- Hernandez-Gea, *et al.*

Time to rethink TIPS.

Learn more at goremedical.com/rethinkTIPS

Please contact your Gore technical sales associate if you have further questions.

* For a combined group of patients with Child-Pugh C (CP-C) score ≤ 13 or Child-Pugh B with active bleeding (CP-B + AB) at diagnostic endoscopy.

† For Child-Pugh C patients with scores ≤ 13 .

‡ One-year actuarial probability of remaining free of failure to control bleeding and of variceal rebleeding.

§ Primary study end point is composite outcome of failure to control acute bleeding or to prevent clinically significant variceal rebleeding. Data is presented as percentage that did not present the composite outcome.

|| Composite end point of failure to control acute bleeding, early rebleeding, and late rebleeding. Data as presented is for CP-B + AB and CP-C patients combined.

1. García-Pagán JC, Caca K, Bureau K, *et al*; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. *New England Journal of Medicine* 2010;362(25):2370-2379.

2. Garcia-Pagán JC, Di Pascoli M, Caca K, *et al*. Use of early-TIPS for high-risk variceal bleeding. Results of a post-RCT surveillance study. *Journal of Hepatology* 2013;58(1):45-50.

3. Hernández-Gea V, Procopet B, Giráldez Á, *et al*; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. *Hepatology* 2019;69(1):282-293.

 Consult Instructions for Use

Refer to *Instructions for Use* for a complete description of all warnings, precautions, and contraindications. [®] Only

Products listed may not be available in all markets.

GORE, *Together, improving life*, VIATORR and designs are trademarks of W. L. Gore & Associates, Inc.

© 2019 W. L. Gore & Associates, Inc. AUGUST 2019

W. L. Gore & Associates, Inc.

Flagstaff, AZ 86004

Asia Pacific +65 67332882 Europe 00800 6334 4673

United States 800 437 8181 928 779 2771 goremedical.com



AY0626-ENI